Neuro-focused Lundbeck divests US product portfolio to Recordati for $100m
This article was originally published in Scrip
Executive Summary
Italian firm Recordati has acquired a portfolio of products for the treatment of rare and other diseases from H Lundbeck for $100 million, all of which are marketed mainly in the US. The products gave Lundbeck 2011 revenues of $45 million, and are expected to bring in 2013 revenues of around $40 million.